A genetic variant of fatty acid amide hydrolase (FAAH) exacerbates hormone-mediated orexigenic feeding in mice
Fatty acid amide hydrolase (FAAH) degrades the endocannabinoid anandamide. A polymorphism in FAAH (FAAH C385A) reduces FAAH expression, increases anandamide levels, and increases the risk of obesity. Nevertheless, some studies have found no association between FAAH C385A and obesity. We investigated...
Main Authors: | Georgia Balsevich, Gavin N Petrie, Daniel E Heinz, Arashdeep Singh, Robert J Aukema, Avery C Hunker, Haley A Vecchiarelli, Hiulan Yau, Martin Sticht, Roger J Thompson, Francis S Lee, Larry S Zweifel, Prasanth K Chelikani, Nils C Gassen, Matthew N Hill |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2023-04-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/81919 |
Similar Items
-
Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes
by: Natalia Battista, et al.
Published: (2007-07-01) -
Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review
by: Justin Matheson, et al.
Published: (2021-12-01) -
In Silico and In Vitro Analysis of Major Cannabis-Derived Compounds as Fatty Acid Amide Hydrolase Inhibitors
by: Emanuele Criscuolo, et al.
Published: (2020-12-01) -
Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors
by: Leonardo Brunetti, et al.
Published: (2020-09-01) -
Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen
by: Alessandro Deplano, et al.
Published: (2020-01-01)